The global Chinese Hamster Ovary Cells (CHO) market is likely to grow at a growth rate of 10.3% to reach USD 530.8 million by 2030.

Chinese hamster ovaries refer to the reproductive organs of Chinese hamsters, specifically their ovarian tissue. These cells are of significant interest and utility in scientific research and biotechnology due to their ability to give rise to CHO cells, a commonly used cell line in biopharmaceutical and biomedical research for the production of therapeutic proteins.

Chinese hamster ovaries, which have proven to be immensely valuable, play a pivotal role in generating a cell line known as CHO cells. These CHO cells are regularly harnessed in the fields of medical and biological research, serving as invaluable mammalian hosts, especially in the manufacturing of therapeutic proteins intended for human application.

Request Sample Copy of Report of Global Chinese Hamster Ovary Cells (CHO) Market

The worldwide market for Chinese hamster ovary cells (CHO) is expected to experience growth due to rising investments aimed at expanding the biopharmaceutical sector. Over the past decade, this industry has gained significant importance within the global healthcare and pharmaceutical domains. Biopharmaceuticals have emerged as effective solutions for addressing severe diseases that were previously untreatable through conventional medicines or therapies.

CHO cells exhibit the capacity for human-compatible post-translational modifications, rendering them exceptionally suitable for medicinal and pharmaceutical endeavors, particularly in the domain of protein synthesis. These cells have earned recognition for their proficiency in generating intricate recombinant proteins, thus establishing their indispensable role as a prized asset within the biopharmaceutical sector.

KEY INSIGHTS OF THIS REPORT:

• In terms of application breakdown, it was forecasted that monoclonal antibodies would command the largest market share in 2022.
• Within the realm of end-user categorization, biopharmaceutical companies emerged as the predominant users in the year 2022, primarily due to their substantial demand for Chinese hamster ovary cells (CHO) in the production of biopharmaceuticals.
• In 2022, North America stood out as the top contributor to revenue, largely attributed to its robust economic activity, well-established industries, and significant market demand across various sectors.

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET SEGMENTATION

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET KEY PLAYERS

• Promega Corporation
• Aragen Life Sciences Pvt. Ltd.
• Thermo Fisher Scientific
• Cygnus Technologies
• Selexis SA
• trenzyme GmbH
• JSR Life Sciences, LLC
• Merck KGaA
• WuXi Biologics
• CELONIC Group
• WuXi Biologics
• ProBioGen AG
• Others

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY PRODUCT TYPE

• CHO- DG44
• CHO-DXB1
• CHO-K1
• CHO-S
• Others

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY SYSTEM

• Metabolic Selection System
• Antibiotic Selection System

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY APPLICATION

• Hormones
• Monoclonal antibodies
• Fc- Fusion Protein
• Clotting Factors
• Cytokines
• Enzymes
• Others

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY END-USERS

• Biotech Companies
• Biopharmaceutical Companies
• Clinical Development & Manufacturing Organization
• Academic Institutes and Research
• Clinical Research Organizations
• Others

GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY REGION

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
• Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
• The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA